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Introduction: To evaluate the perception of lung cancer in the general 
population to identify obstacles in patient–doctor communications.
Methods: A prospective nationwide survey was conducted using a 
questionnaire and lexical approaches given to 2200 healthy subjects 
selected within a representative polling database.
Results: Of the 1469 subjects eligible for full analysis, most were 
well informed regarding the epidemiological changes to lung cancer 
and the main risk factors. The overall survival of patients with lung 
cancer (32%) was overestimated, and the survival of patients with 
early stages of lung cancer was underestimated (52%). Lung cancer 
was identified as a severe disease (82%) with a worse prognosis than 
other cancers. Most of the population was aware of the main treat-
ments available, except for targeted therapy. Using lexical analyses, 
we observed that a major proportion considered lung cancer to be a 
tobacco-induced, life-threatening disease that involved major treat-
ment, and a minor proportion considered it to be an environmen-
tally induced disease. Compared with breast cancer, lung cancer was 
characterized by a greater feeling of guilt and was more frequently 
associated with lifestyle.
Conclusions: We have identified knowledge gaps in the perception 
of lung cancer and have highlighted a need for a public information 
campaign on lung-cancer screening to promote the good survival rate 
from early-stage disease and the progress achieved with new thera-
peutic strategies.
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(J Thorac Oncol. 2015;10: 420–425)
Lung cancer is the most common cause of cancer-related deaths, and its prognosis remains poor, with an overall 
survival rate of less than 15%.1 Lung cancer is a disease of 
high symptom burden and has major psychological impact. 
Psychological distress because of lung cancer is higher than 
that because of other cancers, and there are large unmet psy-
chosocial concerns. As it is frequently associated with life-
style, and particularly smoking, lung cancer is often socially 
represented as a self-inflicted disease.2 Therefore, for the 
patient, a diagnosis of lung cancer is often associated with 
feelings of guilt and a high level of anxiety.3
These feelings are probably associated with delayed 
diagnosis and the fear of the inefficacy of some anticancer 
treatments. Because the majority of cases are diagnosed later, 
only around 20% of lung cancers are operable at the time of 
diagnosis, as clinical symptoms usually only appear at a later 
stage and are not specific. Moreover, delays between the first 
symptoms and a specialist visit, and then between the first visit 
and beginning treatment, are long,4,5 often exceeding 2 months 
in France. Conventional front-line chemotherapies used in 
unselected patients reached a plateau of efficacy, which led 
to a pessimistic view of lung cancer in the late 1990s includ-
ing within the general population, especially as other cancers, 
such as breast cancer or hematological malignancies, seemed 
to benefit from medical progress.6
However, lung-cancer management has evolved rap-
idly with the advent of new chemotherapies, the validation 
of maintenance treatment, the development of targeted drugs, 
improvements in surgery and radiotherapy in both early and 
locally advanced stages of this disease, and the greater poten-
tial interest in lung-cancer screening.7–13 After years of very 
slow progress, these recent advances provide scope for a dra-
matic improvement in the perception of this disease by both 
patients and physicians. In clinical practice, medical staffs are 
often largely unaware of how the patient perceives and feels 
about their disease. One of the main sources of psychological 
distress that patients may experience is linked with social per-
ceptions and the cultural context in which events take place.
Herein, we have evaluated perceptions of lung cancer 
in the general population to better anticipate fears or failures 
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that could alter physician–patient communications and delay 
lung-cancer screening and diagnosis. We have conducted (in 
France) a prospective observational survey of 2200 healthy 
subjects older than 18 years and collected data related to eti-
ology, epidemiology, diagnosis (including screening), treat-
ments, prognosis, and perceptions of lung cancer using lexical 
approaches.
PATIENTS AND METHODS
General Considerations
This prospective study was designed not only by an 
interdisciplinary group of oncologists involved in lung-
cancer management, but also by chest physicians, general 
practitioners, and social psychologists not involved in lung-
cancer treatment. The survey was conducted in France by 
Kantar Health, a market-research company. All data collected 
were anonymous, and the French Data Protection Authority 
(Commission Nationale Informatique et Libertés) was notified 
of the study (registration number: 117856). The research was 
conducted according to the relevant national and European 
laws, and professional guidelines. All participants enrolled 
in the study were informed of the objectives of the research, 
how the data would be used, and their right to withdraw their 
answers from the study.
Population
The general population was selected from the ACCESS 
SANTE permanent polling database, representative of the 
French population aged ≥18 years and living in France in 
June 2013. Its representativeness and the algorithms used 
in sample selection have been verified by experts from the 
National Institute for Statistics and Economic Studies (Institut 
National de la Statistique et des Etudes Economiques, France) 
and EUROSTAT (Europe). Subjects entered into this database 
were accrued in several ways (face-to-face interviews, phone 
calls, and e-mail invitation), in an attempt to reduce the possi-
ble risk of selection bias associated with a particular method.
The panelists participate in six to eight health surveys 
per year and receive nonmonetary incentives in return for their 
participation. The panel was composed of 20,000 households 
(including 53,000 individuals), selected according to standard 
sociodemographic and geographic criteria. The representa-
tiveness of the sample was assessed using the quota method, 
and computerized weighting was used according to the raking 
adjusted statistics method. To ascertain that the sample was 
representative of the overall national population, a weighting 
was applied based on five criteria: gender, age (five catego-
ries), socioprofessional status (eight categories), region (nine 
categories), and community size (five categories).
A self-administered questionnaire was posted to a 
selected representative sample of 2200 participants from 
the general public who were aged ≥18 years, using quota 
sampling.
Questionnaire
Questions were asked about age, gender, place of resi-
dence, smoking, socioeconomic characteristics (educational 
level and working status), and whether or not they had person-
ally been in contact with someone who had experienced lung 
cancer. Also, questions regarding their knowledge of epide-
miology, symptoms, treatment, prognosis, screening for lung 
cancer, and how they evaluated their own level of knowledge 
about lung cancer were asked.
Lexical Tests
At the beginning of the questionnaire, subjects were 
proposed a test of verbal association. They were asked to 
spontaneously associate five words with “lung cancer.” The 
test was performed by 96% of the subjects (n = 1429) leading 
to a total of 7839 words. The lexical corpus was performed 
using the lexicometric-derived approach, called ALCESTE.14 
This procedure uses repeated, descending hierarchical cluster-
ing. It is a two-by-two matrix that compares how words co-
occur (or not) in each extract and develops a classification tree 
that is descendant because the whole corpus is divided first 
into two main lexical classes according the greatest difference 
between the use of any two words. Then, for each of these two 
classes, the software redivides the text into two other different 
parts and continues this classification until the lexical classes 
become stable and autonomous.
Statistics
Results are expressed as percentages or means + stan-
dard deviations. Analyses were performed using CromX 
(SocioLogiciel, France). The p values less than 0.05 (two-sided 
tests) were considered statistically significant.
RESULTS
Demographic Characteristics
Of the 2200 people identified from the database, 1469 
were eligible for the full analysis (Fig. 1). These 1469 people 
were representative of the whole population, and there was 
no selection bias because similar demographic characteristics 
were observed in both populations (see Supplemental Table, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A752). In this population, 16% were current smokers, 27% 
were former smokers, and 57% were never-smokers. Forty 
percent had a close family member or friend with a history of 
lung cancer.
FIGURE 1.  The CONSORT diagram.
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Knowledge of the Epidemiology and 
Risk Factors for Lung Cancer
The participants were asked about the epidemiological 
changes in the incidence of lung cancer over the past 10 years. 
Regarding the incidence of lung cancer in men, the response 
“the same” (the correct response), “higher,” or “lower” was 
given by 40%, 47%, and 12% of the public, respectively. Most 
participants were familiar with the epidemiological changes 
in incidence in women: the correct response of “higher” was 
given by 75% of the participants.
The main beliefs on the causes of lung cancer, as a per-
centage of the listed causes, are summarized in Figure 2. The 
vast majority of participants were familiar with the role of 
active smoking (93%), whereas only two-thirds (67%) were 
aware of the role of passive smoking.
Of the 1469 participants, 22% considered themselves to 
be at risk of developing lung cancer (see Supplemental Table, 
Supplemental Digital Content 2, http://links.lww.com/JTO/
A752). The perceived risk was significantly higher for smokers 
(62%) than for former smokers (21%) and never-smokers (6%) 
(p <0.001), for younger than for older subjects (p = 0.006), and 
for more men (26%) than women (19%, p = 0.009).
Knowledge of the Symptoms and Prognosis
The first question concerned the initial symptoms of 
the disease. We observed that 85% of the general population 
believed that symptoms are present in most cases. Lung can-
cer was considered a severe cancer by the vast majority (83%).
Participants were asked to give their opinion about five 
other cancers on a scale of 1 to 10: pancreatic cancer was 
considered severe (80% of the participants), whereas colorec-
tal, breast, and prostate cancers were regarded as less serious 
(59%, 38%, and 36% of participants, respectively; Fig. 3A). 
We analyzed the data according to gender and found no dif-
ferences in the perception of the seriousness of lung cancer 
between men and women, whereas differences were observed 
in the concept of seriousness of breast cancer, with women 
considering this more serious than men. We also analyzed the 
perception of cure rate of lung cancer and observed that 32% 
of the public think that lung cancer can be cured at any stage 
and 52% if diagnosed at an early stage (presented in the sur-
vey as “a very early stage”; Fig. 3B). The perceived cure rate 
for other cancers was higher for breast, prostate, and colorec-
tal cancers and similar for pancreatic cancer (Fig. 3B).
Knowledge of Lung-Cancer Treatments
When lung-cancer treatments were listed and suggested 
to the participants, the best known were chemotherapy (91%), 
stopping smoking (90%), surgery (71%), radiotherapy (64%), 
treatment of symptoms (48%), targeted treatments (45%), and 
alternative therapies (15%; Fig. 4). When asked their opin-
ion on the treatment of lung cancer, most participants thought 
that lung-cancer treatment required overnight hospitalization 
(74%), that treatment had to be administered by perfusion to 
be efficient (60%), that chemotherapy alone was sufficient 
FIGURE 2.  Beliefs about the causes of lung cancer (percent-
ages of listed causes).
FIGURE 3. A, Assessing the gravity 
of five cancers. Answers to the ques-
tion: “On a scale of 0–10, how would 
you rate the seriousness of these can-
cers?” B, Average percentage chance 
of a cure from five types of cancer at 
all stages (B-left panel) or at any one 
stage (B-right panel).
423Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 3, March 2015 Perception of lung cancer in the general population
(44%), and 21% thought that alternative medicine could effi-
ciently treat lung cancer (see Supplemental Fig., Supplemental 
Digital Content 3, http://links.lww.com/JTO/A752).
Perception of Lung Cancer: 
Lexical and Thematic Fields
Participants were invited to spontaneously associate their 
perceptions of lung cancer. Analysis of the 10 most frequent 
words in the lexical corpus (n = 7839 words, 5.4 per person) 
showed a tendency to associate the expression “lung cancer” 
with tobacco use (“cigarette,” “smoking,” and “tobacco” were 
cited 1017 times in total), a fatal disease (“death” was cited 
535 times), pollution (n = 231), chemotherapy-based treat-
ments (n = 337), and suffering. (n = 276). The main repertoires 
for the lexical corpus, deciphered by performing a descend-
ing hierarchical clustering and taking into account the socio-
demographic profile of the subjects, are shown in Table 1. 
Briefly, from a thematic point of view, the corpus could be 
split into two main lexical repertoires. The major repertoire 
(85% of the corpus) brought out words, such as tobacco, asso-
ciated with death (32.2%) or cure (25.3%), the color black 
and symptoms (cough, fatigue, shortness of breath). For the 
lexical field of “death,” disease, hospital, and suffering were 
predominantly more associated by younger (18–34 years old) 
smokers, whereas lung, black color, and respiratory symptoms 
were chosen more by women aged 35–49 years. In the minor 
repertoire (15%), lung cancer was associated with risk fac-
tors (pollution, asbestos, chemical products, pesticides) and 
lifestyle (work, hygiene). This lexical field was preferentially 
responded to by the elderly and nonsmokers.
Perception of Lung Cancer: 
Comparison with Breast Cancer
Comparisons between perceptions of lung cancer and 
breast cancer demonstrated that breast cancer was signifi-
cantly more frequently considered as a twist of fate, an injury, 
or an attack, whereas lung cancer was more frequently associ-
ated with the loss of autonomy or a punishment (Fig. 5).
DISCUSSION
Most of the studies published in this field are retrospec-
tive and focus on patients with lung cancer or medical stu-
dents, but very few have included the general population.15,16 
Moreover, most published studies were performed at a time 
when patients with lung cancer had a very pessimistic outlook 
because of the absence of novel treatments.
The originality of our study is our screening of a large 
number of the general population at a crucial period when 
lung-cancer management is rapidly evolving. However, 
our study was restricted to the French population; thus, our 
conclusions cannot be fully extended to other countries. 
Nevertheless, we think that the perception of lung cancer in 
France, despite some specificities, is probably close to that in 
other developed countries, as epidemiologic and therapeutic 
changes have evolved similarly worldwide. One limitation 
of our study can be that the percentage of smokers (16%) 
is lower than the usually reported percentage of smokers in 
France (30%). This gap might be explained by the fact that 
nonsmokers are more likely to respond than smokers.
We have analyzed the perception of risk factors and epi-
demiology of lung cancer. Li et al.17 showed that knowledge 
and beliefs about lung cancer varied significantly according 
to smoking status, never-smokers being the most knowledge-
able about tobacco-related cancer risk. We found that the link 
of causality between lung cancer and smoking habits is well 
known in the general population. Nevertheless, we observed 
striking differences in the knowledge of other risk factors. The 
general population also appears to be aware of the potential 
carcinogenicity of occupational exposure, air pollution, and 
ionizing radiation. These risk factors have been extensively 
studied and are known to cause lung cancer, even if the rela-
tionship is weaker than those for active smoking.18 Recently, 
the role of diesel particles has been reported to be a risk factor 
FIGURE 4.  Knowledge of the main lung cancer treatments.
TABLE 1.  Lexical Field Analysis
Main Words Chosen  
(% of the Total Corpus)
Three Most  
Significant Words (χ2) Significant Sociodemographic Variables
Lexical clusters Death (32.2%) Death (209), hospital (113), suffering (79.2) Smokers, 18–34 yrs, professionally active
Cure (25.3%) Cure (93.8), hope (55), treatment (49.7) Aged >65 yrs, non-active, low instruction level.
Black (18%) Breath (145), cough (62.5), lung (79.1) Non-smokers, women, 35–49 yrs, active, high level 
of education, urban lifestyle
Fatigue (9.5%) Fatigue (228.4), radiotherapy (194), being out of 
breath (184.1)
Former smokers, rural lifestyle
Pollution (15%) Pollution (273.4), chemical product (198.2), 
asbestos (219)
Nonsmokers, men, aged >65 yrs, nonactive.
Ten most frequent words are as follows: death (n = 535), tobacco (n = 453), cigarettes (n = 426), chemotherapy (n = 337), disease (n = 283), suffering (n = 276), pollution (n = 231), 
pain (n = 193), smoking (n = 138), asbestos (n = 132). In total (tobacco, cigarettes, and smoking) n = 1017.
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for lung cancer.19 In contrast, few data support the role of food 
in lung carcinogenesis. However, a third of the general popu-
lation cited alimentation as a risk factor, probably because of 
the recent literature that targets the general public more than 
physicians. The role of passive smoking was unknown by a 
third of the population, even though the role of passive smok-
ing has been very well documented and is associated with 
600,000 deaths worldwide every year, among which 21,400 
are caused by lung cancer.20
Interestingly, smoking habits strongly influence the 
perception of the risk of lung cancer. As expected, the risk 
was perceived as significantly higher by smokers than by 
nonsmokers. In contrast, the risk was underestimated by for-
mer smokers. In summary, the general population appears to 
be aware of the main risk factors for lung cancer, but effort 
should be made to improve education that passive smoking is 
also a well-recognized risk factor.
We also analyzed the general public’s knowledge of 
lung-cancer symptoms. Surprisingly, a large majority think 
that lung cancer is symptomatic in the early stages of the dis-
ease. There is probably confusion, as lung cancer is known to 
be symptomatic at a metastatic stage. Lung cancer is indeed 
known to be associated with the worst pain intensity and 
higher mean depression scores compared with that of other 
cancers.21 This observation should be taken into account as 
lung-cancer screening has been validated by recent studies.13 
Effort should be made to convince the general population that 
lung cancer is not symptomatic in its early stages and that the 
best survival is observed with small asymptomatic lung can-
cer, which can benefit from surgery. It is well known that the 
efficiency of a screening program is directly related to public 
awareness and that a diagnosis performed before the onset of 
symptoms is associated with better survival.
We have entered a new and hopeful era in the treat-
ment of lung cancer. In recent years, there have been some 
exciting developments in lung-cancer treatments, especially 
concerning improvements in surgery to treat early-stage 
patients (videothoracoscopy), alternative procedures for inop-
erable patients (stereotactic radiotherapy, thermoablation), 
new radiotherapeutic strategies (tomotherapy, gating, and 
intensity-modulated radiotherapy), and the development of 
new targeted drugs based on a better understanding of lung 
oncogenesis.22 Awareness in the general public of these prom-
ising developments should change the pessimistic approach 
to lung cancer. Interestingly, although patients were aware of 
the main cancer treatments, e.g., surgery, radiotherapy, and 
chemotherapy, they had poor knowledge of the new tools in 
radiotherapy or of targeted agents. Effort in this area may help 
enroll more patients into clinical-research programs that are 
evaluating targeted drugs.
The perception of prognosis is a key issue in patient–
doctor communication. Sagan et al. showed that patients with 
lung cancer perceive their disease more optimistically than 
medical personnel, but this study did not include healthy indi-
viduals from the general population. We also observed that the 
public overestimated the 5-year survival rate from lung can-
cer (32% compared with the actual survival rate of 15%).16,23 
Conversely, the public underestimated the rate of definitive 
cure by surgery for early-stage lung cancer.24 Moreover, the 
high rate of cure at the early stages is the basis of the lung-
cancer screening program. Rutten et al.25 showed that only a 
minority of respondents (17%) correctly evaluated the prog-
nosis of lung cancer, in contrast to colon and skin cancers. In 
a recent prospective study, 69% of patients with lung cancer 
believed that chemotherapy might be curative.26
According to the lexical approaches, the general popula-
tion perceived lung cancer as a life-threatening disease asso-
ciated with a high symptom burden: fatigue, cough, pain, and 
shortness of breath were cited frequently. Gralla et al.27 noted 
that more than 80% of patients with lung cancer are affected 
by at least three symptoms (including the most common, e.g., 
pain, dyspnea, and fatigue). This explained the patient’s social-
function impairment and the contribution to intrusive thoughts 
(references to death, fatigue, symptoms). Another interesting 
finding was that lung cancer was more often associated with 
a loss of autonomy and was considered a punishment. Doctors 
should be aware of this, so that they can diminish this associa-
tion. Patients’ associations, which are less developed for lung 
cancer than for breast cancer, should also help patients and their 
families have a better perception of this disease. Therapeutic 
burden by itself also contributes to this social representation of 
the disease, probably because most of the general population is 
aware of the impact that a patient’s treatment can have on daily 
life and possible changes in family and social status.
FIGURE 5.  Comparison of how lung cancer and 
breast cancer feel to the patient. In response to the 
question “According to you, how does a patient 
with lung/breast cancer consider their disease?”
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In conclusion, our work may help to identify psycho-
logical obstacles in effective patient–doctor communications, 
to fill the knowledge gap in the perception of some aspects 
of this disease, and thus improve lung-cancer management. A 
large public information campaign concerning the potential 
benefits of lung-cancer screening, the good survival rate from 
early-stage disease, and the progress observed with new thera-
peutic strategies, such as targeted therapies, is needed.
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